Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case Report.
Secondary plasma cell leukemia (sPCL) is a rare, aggressive manifestation of multiple myeloma (MM).
APA
Suzuki T, Yokomori R, et al. (2026). Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case Report.. EJHaem, 7(1), e70215. https://doi.org/10.1002/jha2.70215
MLA
Suzuki T, et al.. "Whole Genome and Single-Cell RNA Sequencing Reveals Clonal Evolution and Heterogeneity of Secondary Plasma Cell Leukemia: A Case Report.." EJHaem, vol. 7, no. 1, 2026, pp. e70215.
PMID
41542018
Abstract
Secondary plasma cell leukemia (sPCL) is a rare, aggressive manifestation of multiple myeloma (MM). We report a 75-year-old Japanese man with anemia as the chief complaint and IgG-λ MM that rapidly progressed to sPCL. Whole genome sequencing using Canopy revealed a major clone with a monoallelic mutation. During progression, a subclone with a biallelic mutation expanded, and the 1q21 copy number increased. Single-cell RNA-sequencing identified an emergent PCL population with high CKS1B expression. These data demonstrate genomic instability and clonal evolution during sPCL development, underscoring the need for approaches accounting for tumor heterogeneity in MM. : The authors have confirmed clinical trial registration is not needed for this submission.
같은 제1저자의 인용 많은 논문 (5)
- Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.
- Combined Large Cell Neuroendocrine Carcinoma of the Endometrium Treated With Paclitaxel, Carboplatin, and Durvalumab, Followed by Maintenance Therapy With Durvalumab and Olaparib (DUO-E Regimen): A Case Report.
- The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study.
- A Case of Acute Myeloid Leukemia with MOZ::TIF2 Fusion Gene Resulting from a Novel Breakpoint.
- Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma.